Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Liraglutide

A Study to Evaluate the Efficacy and Safety of MEDI0382 in the Treatment of Overweight and Obese Subjects With Type 2 Diabetes

Novo Nordisk · Phase 2 · Completed · Enrollment 834

NCT03235050

ArmPopulationDoseWeeksEstimandWeight change
MEDI0382 low dose + MetforminT2D onlyn/rn/rn/rn/r
MEDI0382 mid dose + MetforminT2D onlyn/rn/rn/rn/r
MEDI0382 high dose + MetforminT2D onlyn/rn/rn/rn/r
Placebo + MetforminT2D onlyn/r14n/rn/r
Liraglutide + MetforminT2D onlyn/rn/rn/rn/r
MEDI0382 100 mcgT2D only100 mcg14n/rn/r
MEDI0382 200 mcgT2D only200 mcg14n/rn/r
MEDI0382 300 mcgT2D only300 mcg14n/rn/r